Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

Not long after netting $57m in financing, Inflammatix has kick started a clinical trial evaluating its technology for the ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC) said: “The third quarter was truly ...